Editorial
Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 7, 2018; 24(29): 3201-3203
Published online Aug 7, 2018. doi: 10.3748/wjg.v24.i29.3201
Upfront surgery of small intestinal neuroendocrine tumors. Time to reconsider?
Kosmas Daskalakis, Apostolos V Tsolakis
Kosmas Daskalakis, Department of Surgical Sciences, Uppsala University, Uppsala 75185, Sweden
Apostolos V Tsolakis, Department of Oncology and Pathology, Karolinska Institute, Stockholm SE-171 76, Sweden
Apostolos V Tsolakis, Cancer Center Karolinska, Karolinska University Hospital Solna R8:04, Stockholm SE-171 76, Sweden
Apostolos V Tsolakis, Department of Gastrointestinal Endoscopy, Karolinska University Hospital Huddinge, Stockholm SE-141 86, Sweden
Author contributions: Daskalakis K and Tsolakis AV both designed and wrote the editorial.
Conflict-of-interest statement: The authors state that they do not have any conflict of interest to declare.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Apostolos V Tsolakis, MD, PhD, Doctor, Staff Physician, Department of Gastrointestinal Endoscopy, Karolinska University Hospital Huddinge, Stockholm SE-141 86, Sweden. apostolos.tsolakis@ki.se
Telephone: +46-8-58580000
Received: June 1, 2018
Peer-review started: June 1, 2018
First decision: July 4, 2018
Revised: July 9, 2018
Accepted: July 16, 2018
Article in press: July 16, 2018
Published online: August 7, 2018
Core Tip

Core tip: Upfront locoregional resective surgery of small intestinal neuroendocrine tumors is the mainstay treatment when radical resection is feasible or when symptoms are present, regardless of the disease stage. However, in the light of contemporary evidence, the traditional upfront surgical approach is challenged regarding patients with distant metastases without local tumor-related symptoms.